share_log

CVS Health | 8-K: Current report

CVS Health | 8-K: Current report

西维斯健康 | 8-K:重大事件
美股SEC公告 ·  12/06 02:35

Moomoo AI 已提取核心信息

On December 3, 2024, CVS Health entered into an Underwriting Agreement with Barclays, Citigroup, and Goldman Sachs to issue $3 billion in Junior Subordinated Notes. The issuance includes $2.25 billion of 7.000% Series A Notes due 2055 and $750 million of 6.750% Series B Notes due 2054.The sale is expected to close on December 10, 2024, subject to customary conditions. Net proceeds, after underwriters' discounts and expenses, are estimated at approximately $2.96 billion. The Notes are offered under CVS Health's Registration Statement on Form S-3ASR.Forward-looking statements in the report highlight potential risks and uncertainties. CVS Health advises caution in relying on these statements, as actual results may differ materially due to various factors outlined in their SEC filings.
On December 3, 2024, CVS Health entered into an Underwriting Agreement with Barclays, Citigroup, and Goldman Sachs to issue $3 billion in Junior Subordinated Notes. The issuance includes $2.25 billion of 7.000% Series A Notes due 2055 and $750 million of 6.750% Series B Notes due 2054.The sale is expected to close on December 10, 2024, subject to customary conditions. Net proceeds, after underwriters' discounts and expenses, are estimated at approximately $2.96 billion. The Notes are offered under CVS Health's Registration Statement on Form S-3ASR.Forward-looking statements in the report highlight potential risks and uncertainties. CVS Health advises caution in relying on these statements, as actual results may differ materially due to various factors outlined in their SEC filings.
2024年12月3日,CVS Health与巴克莱、花旗集团和高盛签订了承保协议,发行30亿美元的初级次级票据。本次发行包括2055年到期的22.5亿美元7.000%的A系列票据和2054年到期的7.5亿美元6.750%的b系列票据。此次销售预计将于2024年12月10日结束,但须遵守惯例。扣除承销商折扣和支出后的净收益估计约为29.6亿美元。这些票据是在 CVS Health 的 S-3ASR 表格注册声明下提供的。报告中的前瞻性陈述突显了潜在的风险和不确定性。CVS Health建议谨慎依赖这些陈述,因为由于美国证券交易委员会文件中概述的各种因素,实际结果可能会有重大差异。
2024年12月3日,CVS Health与巴克莱、花旗集团和高盛签订了承保协议,发行30亿美元的初级次级票据。本次发行包括2055年到期的22.5亿美元7.000%的A系列票据和2054年到期的7.5亿美元6.750%的b系列票据。此次销售预计将于2024年12月10日结束,但须遵守惯例。扣除承销商折扣和支出后的净收益估计约为29.6亿美元。这些票据是在 CVS Health 的 S-3ASR 表格注册声明下提供的。报告中的前瞻性陈述突显了潜在的风险和不确定性。CVS Health建议谨慎依赖这些陈述,因为由于美国证券交易委员会文件中概述的各种因素,实际结果可能会有重大差异。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息